Handelsavisen
prelaunch
Companies Healthcare AMED.O
AM
AMED.O NASDAQ Health Care Providers & Services

Amed.O

Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
4,1 %
ROE
7,5 %
Net margin
3,6 %
Debt / equity
0,33
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.

Business. AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.

Classification85 %
SectorHealth Care
Industry groupHealth Care Providers & Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability
7,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AMED.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,7 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,4 %−2,7 %−0,9 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Consumer Staples−0,7 %+2,3 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AMED.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressLisa McClain — Amedisys Inc - Common Stock2025-08-18 · Republican · MI · Sale · $1,001 - $15,000
    • CongressLisa McClain — Amedisys Inc - Common Stock2025-06-09 · Republican · MI · Purchase · $1,001 - $15,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    AMED.O operates within the Health Care Providers & Services industry, generating revenue through healthcare-related activities, though specific operational details are unclassified in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupHealth Care Providers & Services
    AI synthesis
    GENERATED

    AMED.O maintains a conservative capital structure with a debt-to-equity ratio of 0.33 and a current ratio of 1.23, indicating adequate short-term liquidity despite a medium liquidity risk assessment. The balance sheet shows total assets of $2.14 billion against total liabilities of $1.00 billion, resulting in total equity of $1.13 billion. The company holds $303.2 million in cash and equivalents, which partially offsets its $377.3 million in long-term debt, leading to a net cash position that is technically negative when total debt is considered, as flagged in the risk assessment.

    Profitability metrics indicate modest returns, with a return on equity (ROE) of 7.55% and a return on assets (ROA) of 4.0%. The company generated $2.35 billion in revenue, resulting in a gross profit of $1.02 billion and an operating income of $94.5 million. Net income stands at $43.2 million, reflecting a net margin of approximately 1.84%. These returns are derived from a business model that generates significant gross margins but faces substantial operating expenses, compressing bottom-line profitability.

    Segment and geographic data are not provided in the available input, preventing a detailed analysis of revenue concentration or regional exposure. The classification source indicates the company operates in Health Care Providers & Services, but without specific segment breakdowns, the revenue mix remains opaque. The lack of segment data limits the ability to assess diversification risks or identify primary growth drivers within specific business lines.

    Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue and net income, but without year-over-year or quarterly trend data, it is not possible to evaluate the momentum or consistency of the company's financial performance. The latest actual EPS is reported as $4.32, corresponding to the net income of $43.2 million and basic shares outstanding of 32.9 million.

    Risk factors include a medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility. The company's ESG profile shows a total score of 53.75 with a grade of B-, characterized by a strong social pillar score of 66.29 but a weaker environment pillar score of 28.14. The governance pillar scores 51.50, and the controversies score is 79.63, indicating relatively few controversies.

    Recent observations include analyst estimates confirming the last actual revenue of $2.35 billion and EPS of $4.32. No specific filing, news, or transcript events are detailed in the input beyond these standard financial metrics and ESG scores. The company's operational stability appears supported by positive operating cash flow of $221.7 million and free cash flow of $91.3 million, despite the capital expenditure of $7.4 million.

    Key takeaways
    • AMED.O generates $2.35 billion in revenue with a gross profit of $1.02 billion, but net income is compressed to $43.2 million due to operating expenses.
    • The company maintains a conservative leverage profile with a debt-to-equity ratio of 0.33 and a current ratio of 1.23.
    • Returns are modest, with an ROE of 7.55% and ROA of 4.0%, reflecting the margin compression in the healthcare services sector.
    • Liquidity risk is assessed as medium, primarily due to a negative net cash position when total debt is subtracted from cash and equivalents.
    • Dilution risk is low, with basic and diluted shares outstanding being identical at 32.9 million.
    • ESG performance is mixed, with a B- grade driven by strong social scores but weak environmental metrics.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2025-07-29
    Q2 2025 · Quarter highlights

    Revenue $621.9M, +5,2% YoY; Operating income −12,7% YoY.

    Revenue$621.9M+5,2 % YoY
    Operating income$45.6M−12,7 % YoY
    Net income$28.1M−13,1 % YoY
    Free cash flow$43.6M−5,0 % YoY
    EPS
    Operating cash flow$63.5M+38,8 % YoY
    Financials
    Income statement
    Revenue$621.9M
    Gross profit$273.4M
    Operating income$45.6M
    Net income$28.1M
    Margins
    Gross margin44.0%
    Operating margin7.3%
    Net margin4.5%
    FCF margin7.0%
    Balance sheet
    Total assets$2.22B
    Total liabilities$982.9M
    Total equity$1.23B
    Cash & equivalents$337.3M
    Long-term debt$363.2M
    Cash flow
    Operating cash flow$63.5M
    CapEx-$2.3M
    Free cash flow$43.6M
    SBC
    P&L flow · revenue → net income
    Revenue $621.9MOperating costs $576.3MTax $17.5MNet income $28.1M
    Highlights
    • Revenue $621.9M, +5,2% YoY
    • Operating income −12,7% YoY
    • Net income −13,1% YoY
    • Free cash flow −5,0% YoY
    • Net margin 4.5%

    Valuation TTM

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.13B
    Net cash
    -$74.0M
    Current ratio
    1.2
    Debt / equity
    0.3
    ROA
    4.0%
    ROE
    7.5%
    Cash conversion
    259.0%
    CapEx / revenue
    -0.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin4,2 %Above median
    Net Margin3,6 %Above median
    ROE7,5 %Above median
    Capex / Rev-0,3 %Below median
    D/E0,33Below median
    Cash Conv2,59Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    Source documents
    • Amedisys Inc Market data — financials · 2026-08-01
    • Amedisys Inc Market data — analyst estimates · 2026-08-01
    • Amedisys Inc Market data — ESG · 2026-08-01

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$285M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$5M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AMED.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2025-09-01CONGRESSLisa McClain (house) sale shares → $1,001 - $15,000
    2025-08-13CONGRESSLisa McClain (house) purchase shares → $1,001 - $15,000
    2025-07-29 16:58 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 621.9M · Net USD 28.1M
    2025-04-23 16:45 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 594.8M · Net USD 61.0M
    2025-02-26 16:30 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 598.1M · Net USD -20.4M
    2025-02-26 16:30 UTCEARNINGSAnnual results — FY 2025 Revenue USD 2.35B · Net USD 43.2M
    2024-11-06 16:32 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 587.7M · Net USD 16.9M
    2024-07-24 16:33 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 591.2M · Net USD 32.3M
    2024-04-24 16:48 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 571.4M · Net USD 14.4M
    2024-02-21 16:30 UTCEARNINGSQuarterly results — Q4 2023 Revenue USD 570.8M · Net USD 19.3M
    2024-02-21 16:30 UTCEARNINGSAnnual results — FY 2024 Revenue USD 2.24B · Net USD -9.7M
    2023-10-24 16:33 UTCEARNINGSQuarterly results — Q3 2023 Revenue USD 556.2M · Net USD 26.0M
    2023-02-15 16:10 UTCEARNINGSAnnual results — FY 2023 Revenue USD 2.22B · Net USD 118.6M
    2022-02-23 16:14 UTCEARNINGSAnnual results — FY 2022 Revenue USD 2.21B · Net USD 209.1M
    2021-02-24 16:09 UTCEARNINGSAnnual results — FY 2021 Revenue USD 2.07B · Net USD 183.6M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage